Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
This activity is supported by an educational grant from Lilly.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
In order to request this CME/CE activity for your center, please contact Samantha Miller at Smiller@gotoper.com or call (609) 325-4808
Oncology Best Practice™:
Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease Progression
September 2017 - January 2018
The management of patients with advanced non–small cell lung cancer (NSCLC) who have progressed following first-line therapy has increased in complexity due to the expanding subtypes of NSCLC and corresponding therapeutic options recently made available. As new biomarkers and patient characteristics continue to emerge that assist clinicians in predicting responsiveness to particular approaches, practitioners will need updates that allow them to optimize outcomes in lung cancer management. Education is therefore needed to address the evidence that informs therapeutic selection after disease progression, circumstances that should guide switching of therapies, and methods to proactively manage treatment-related adverse events.
To meet this educational need, Oncology Best Practice™ will bring nationally renowned experts in NSCLC directly to leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. These 1-hour interactive meetings will address the therapeutic needs that persist for patients with lung cancer, as well as current and emerging therapies to address these medical needs. Ample discussion time will allow participants to interact with expert faculty to address challenges in their practice.
What will attending an Oncology Best Practice™ allow me to do?
This educational activity is directed toward medical oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are invited to participate.
At the conclusion of this activity, participants will be better prepared to:
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Feb 10, 2018
February 10, 2018
New York, NY
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Feb 28, 2018
Feb 28, 2018
Feb 28, 2018